Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Multiple Myeloma 1Melanoma 1HIV Infections 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 68Paclitaxel 32Radiotherapy 31Carboplatin 23Bevacizumab 21pembrolizumab 20Brachytherapy 18atezolizumab 11camrelizumab 10Nivolumab 10Gemcitabine 10Drug Therapy 9tislelizumab 8Topotecan 8Taxes 8Chemoradiotherapy 8Radiation 7Docetaxel 7Albumin-Bound Paclitaxel 7zimberelimab 6toripalimab 6nimotuzumab 6Magnetic Resonance Spectroscopy 6Cetuximab 6lenvatinib 5durvalumab 5dostarlimab 5Platinum 5Papillomavirus Vaccines 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Uterine Cervical Neoplasms × Remote Patient Monitoring × Clear all
NCT03834571 2022-06-21

Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women

AIDS Malignancy Consortium

Phase 2 Withdrawn
Gynecologic

Uterine Cervical Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡